← United States · All US Insider Profiles
US INSIDER PROFILE · NON-SCORING RESEARCH
Column Group Opportunity III, LP
10% Owner
Identity: SEC reporting-owner CIK · Reporting-owner CIK: 0001931825
Purchase history
- Companies traded
- 3
- Purchases · 12M
- 7
- Purchases · 24M
- 9
- Average purchase
- $9.1M
- Median purchase
- $1.0M
- Gross purchase value
- $82.1M
Companies: Eikon Therapeutics, Inc. | Surrozen, Inc./DE | Tenaya Therapeutics, Inc.
9 SEC accession(s) · 9 joint-owner event(s). Values are reported Form 4 transaction values in USD.
Qualifying purchase disclosures
| Published | Company | Ticker | Role | Reported value | SEC source |
|---|---|---|---|---|---|
| 2026-09-08 | Eikon Therapeutics, Inc. | EIKN | 10% Owner | $1.0M | Open filing |
| 2026-02-09 | Eikon Therapeutics, Inc. | EIKN | 10% Owner | $38.1M | Open filing |
| 2026-01-20 | Surrozen, Inc./DE | SRZN | 10% Owner | $641.6K | Open filing |
| 2026-01-15 | Surrozen, Inc./DE | SRZN | 10% Owner | $357.3K | Open filing |
| 2026-01-08 | Surrozen, Inc./DE | SRZN | 10% Owner | $300.3K | Open filing |
| 2025-12-08 | Surrozen, Inc./DE | SRZN | 10% Owner | $694.8K | Open filing |
| 2025-11-17 | Surrozen, Inc./DE | SRZN | 10% Owner | $4.0M | Open filing |
| 2025-03-28 | Surrozen, Inc./DE | SRZN | 10% Owner | $12.0M | Open filing |
| 2025-03-07 | Tenaya Therapeutics, Inc. | TNYA | 10% Owner | $25.0M | Open filing |
Post-purchase outcomes
Excess return = stock return − S&P 500 ETF (SPY adjusted close) return. Returns start on the first shared trading session on or after publication.
No completed point-in-time price outcome is available yet.
Research patterns
- First purchase in 12M
- 1/7
- Large purchase ≥ $100k
- 9/9
- Cluster buying · 15D
- 9/9
- Buying the dip
- 0/—
Routine / opportunistic: Not classifiable. These labels never affect the score or ranking.
Small samples remain visible but are not scored. This research enrichment never affects US-v1.1.